Actively Recruiting
Phase I Study to Assess Safety and Effects of CMS-D017 Capsules in Healthy Adults Aged 18 to 55
Led by Shenzhen Kangzhe Biotechnology Co., Ltd. · Updated on 2026-04-08
88
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a first-in-human clinical trial to study CMS-D017 capsules in healthy Chinese adults aged 18 to 55 years. This phase 1 trial aims to evaluate the safety, tolerability, pharmacokinetics how the drug moves through the body, and pharmacodynamics the drugs effects following single and multiple oral doses. The study is randomized, double-blind, and placebo-controlled, including healthy participants without active disease or significant medical conditions. The trial has two parts Part 1 is a single ascending dose SAD study with six dose groups, each having eight participants randomized to receive CMS-D017 or placebo. Part 2 is a multiple ascending dose MAD study with four dose groups, each including ten participants also randomized to drug or placebo. Participants will take the study capsules according to their assigned dosing schedule to assess how the drug behaves after one dose and after multiple doses. Participants will undergo safety monitoring for up to 23 days, including adverse event tracking. Pharmacokinetic and pharmacodynamic measurements will be collected for up to 16 days to assess drug absorption, distribution, metabolism, elimination, and biological effects. The study involves clinical exams, vital signs, ECG, laboratory tests, and questionnaires to evaluate tolerability and drug effects. The total time commitment varies depending on the dosing cohort and study part.
CONDITIONS
Brief Title
A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants
Research Team
Y
Yulan Chen
L
Le Peng
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here